BMY Stock Quote and Market Analysis for Investors

BMY stock has been a solid performer on the market, with its current price per share sitting at around $60.

BMY's strong fundamentals have contributed to its success, including a robust revenue growth rate of 10% year-over-year.

With a market capitalization of over $60 billion, BMY is a large-cap stock that offers stability and growth potential.

Investors looking for a reliable dividend payer may find BMY attractive, as it has a dividend yield of around 4%.

Recommended read: Arihant Capital Market Share Price

BMY's financial performance in 2023 was a mixed bag. Revenue was $45.01 billion, a decrease of -2.50% compared to the previous year's $46.16 billion.

Earnings, however, were a bright spot, increasing by 26.84% to $8.03 billion.

Here's a breakdown of BMY's financial performance in 2023:

Overall, BMY's financial performance in 2023 was a slight decline in revenue, but a significant increase in earnings.

Bristol-Myers Squibb's financial strength is a mixed bag. The company's cash-to-debt ratio is a low 0.16, indicating a significant amount of debt relative to its cash reserves.

You might like: S B I Card Share Price

In contrast, the equity-to-asset ratio is a relatively healthy 0.18, suggesting that the company has a solid foundation of shareholder value.

The debt-to-equity ratio of 3 indicates that the company's debt burden is substantial, but not excessively high.

A debt-to-EBITDA ratio of 10.14 suggests that the company's debt is manageable, given its earnings before interest, taxes, depreciation, and amortization (EBITDA).

The interest coverage ratio of 4.12 indicates that the company has sufficient earnings to cover its interest payments.

The Piotroski F-Score of 5/9 suggests that the company's financial health is somewhat below average, but still stable.

The Altman Z-Score of 1.6 indicates that the company is at risk of distress, but not necessarily in immediate danger.

The Beneish M-Score of -3.08 indicates that the company is unlikely to be engaged in accounting manipulation.

A unique perspective: Compared to Growth Stocks Value Stocks' Price-earnings Ratio Is Typically

The profitability rank is a crucial aspect of a company's financial performance. It shows how well the company is doing in terms of generating profits.

Check this out: B T Share Price Uk

Let's take a look at some key statistics. The company's Gross Margin % is 74.91, which is a strong indicator of its pricing power and ability to maintain profit margins.

This is backed up by its Operating Margin %, which is 15.35. This means that for every dollar of revenue, the company is able to keep 15.35 cents as profit after covering its operating expenses.

However, the company's Net Margin % is a different story. It's -15.3, which means it's actually losing money on a net basis. This is a red flag that the company needs to address.

On a more positive note, the company's FCF Margin % is 29.1. This means that it's generating a significant amount of free cash flow relative to its revenue.

Here's a summary of the company's profitability metrics:

It's worth noting that the company's ROE % is -33.27, which is a significant concern. This means that the company is actually losing money on a return on equity basis.

Similarly, the company's ROA % is -7.66, which is also a red flag. This means that the company is losing money on a return on assets basis.

However, the company's ROIC % is 9.22, which is a positive sign. This means that the company is generating some return on its invested capital.

It's also worth noting that the company has been profitable for 9 out of the past 10 years, which is a positive indicator of its financial health.

BMY stock is a biopharmaceutical company that discovers, develops, licenses, manufactures, markets, distributes, and sells products worldwide.

Their revenue in 2023 was $45.01 billion, a decrease of -2.50% compared to the previous year. Earnings were $8.03 billion, an increase of 26.84%.

The current share price of BMY stock is $60.60, with a 52-week high of $61.10 and a 52-week low of $39.35. The stock has a beta of 0.45, indicating a relatively stable price movement.

Here's a summary of the Zacks Rank and Style Scores:

The stock has seen a 5.06% increase in the last month, a 15.43% increase in the last three months, and a 21.52% increase in the last year.

Bristol-Myers Squibb Company is a global leader in the biopharmaceutical industry, with a diverse portfolio of innovative medicines and a commitment to making a difference in patients' lives.

The company is headquartered in Princeton, New Jersey, and has a presence in over 40 countries worldwide. Bristol-Myers Squibb discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products globally.

The company's revenue was $45.01 billion in 2023, a decrease of 2.50% compared to the previous year's $46.16 billion. Earnings were $8.03 billion, an increase of 26.84%.

Here is a snapshot of the company's financial performance over the past few years:

Bristol-Myers Squibb has a strong track record of innovation, with several key products in its portfolio, including Opdivo and Yervoy. The company has also received regulatory approvals for its products in various markets, including the US and Europe.

The company's stock price has been on an upward trend in recent years, with a current share price of $60.60. The 52-week high and low prices are $61.10 and $39.35, respectively.

Bristol-Myers Squibb has a dividend yield of 4.09%, which is higher than the industry average. The company has a dividend payout ratio of 2.05%, which indicates a relatively stable dividend policy.

The company's growth prospects are also promising, with a 3-year revenue growth rate of 4.8% and a 3-year EBITDA growth rate of 62.2%.

Additional reading: Secular Growth Stocks

Bristol-Myers Squibb faces stiff competition from pharmaceutical giants like Pfizer, which has a market capitalization of over $500 billion.

Pfizer's pipeline includes a range of treatments for various diseases, including cancer and immunology disorders.

AstraZeneca is another major competitor, with a focus on oncology and cardiovascular treatments.

AstraZeneca has a significant presence in the global pharmaceutical market, with a market capitalization of over $100 billion.

Eli Lilly and Company is a well-established player in the industry, with a diverse portfolio of treatments for diabetes, oncology, and other diseases.

Eli Lilly's research and development efforts have led to the development of several innovative treatments in recent years.

Expand your knowledge: Stock Market History